Recombinant Plasmid Therapy for Peripheral Nerve Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating peripheral nerve injuries, such as those involving vascular endothelial growth factor (VEGF) and fibroblast growth factor 2 (FGF2), face challenges in maintaining constant concentrations due to rapid degradation, and existing gene therapies carry risks of insertional mutagenesis and inflammatory responses.
Innovation Solution
Development of a nucleic acid-based therapy using a recombinant plasmid, pBud(Kan)-VEGF-FGF2, which encodes for VEGF and FGF2, administered directly to the site of injury to enhance peripheral nerve regeneration by promoting angiogenesis and neurogenesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If protein-based growth factors (VEGF, FGF2) are used to treat peripheral nerve injuries, then nerve regeneration is promoted, but the growth factors undergo rapid degradation and cannot maintain constant concentration
Solution Approach 1:
The patent uses nucleic acid-based therapy (plasmid vectors) to copy and deliver the genetic instructions for producing growth factors, rather than using the protein growth factors directly. This allows the host cells to continuously produce the growth factors as needed, overcoming the rapid degradation issue of protein-based therapies.
Solution Approach 2:
The patent changes the form of the therapeutic agent from protein (VEGF, FGF2) to nucleic acid (plasmid DNA encoding these factors). This parameter change transforms the therapy from a degradable protein to a stable genetic material that can be replicated and expressed continuously in host cells, thereby maintaining constant concentration and extending duration of action.
2Reliability
If conventional gene therapy vectors are used, then peripheral nerve regeneration is stimulated, but risks of insertional mutagenesis and inflammatory responses occur
Solution Approach 1:
The patent employs non-viral plasmid vectors that do not integrate into the host genome, eliminating the risk of insertional mutagenesis. These plasmids act as temporary, non-integrating carriers that deliver genetic material and then degrade, avoiding the harmful effects of viral integration while maintaining therapeutic effectiveness.
Solution Approach 2:
The patent converts the potential harm of viral vectors (which cause insertional mutagenesis) into a benefit by using non-viral plasmid vectors that deliberately do not integrate. This approach maintains the ability to deliver growth factor genes while eliminating the harmful integration risk, turning a potential harm into a safety feature.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The plasmid-based therapy significantly increases myelinated fibers, capillary formation, and motor function recovery, offering a more reliable and effective treatment for peripheral nerve injuries compared to traditional methods.
Implementation Method 1
a plasmid that encodes and expresses vascular endothelial growth factor (VEGF) and fibroblast growth factor 2 (FGF2) when contacted with or transformed into a tissue
Implementation Method 2
a plasmid that encodes and expresses vascular endothelial growth factor (VEGF) and fibroblast growth factor 2 (FGF2)
Implementation Method 3
VEGF-A is a specific mitogen for endothelial cells (ECs) and induces their proliferation, activation, differentiation and formation of EC capillary tubules. These capillary tubules are further remodeled into mature blood vessels
Implementation Method 4
VEGF also induces expression of antiapoptotic proteins and increases survival of ECs
Implementation Method 5
The plasmid-based therapy significantly increases myelinated fibers, capillary formation, and motor function recovery
Implementation Method 6
The plasmid-based therapy significantly increases myelinated fibers
Data Source
AI summary
Provided is a method for treating a peripheral nervous system damage or injury, or for regenerating peripheral nervous system tissue that involves administering to a subject in need thereof a vector that comprises polynucleotide sequences that encode a modified vascular endothelia growth factor (VEGF) and a fibroblast growth factor (FGF2) and further a polynucleotide that encodes resistance to kanamycin. A gene-therapeutic structure encoding modified vascular endothelial growth factors (VEGF) and (FGF-2) is also provided. The gene-therapeutic structure can be administered directly to a damaged nerve and paraneural tissues both in intraoperative and post-operative period to stimulate peripheral nerve regeneration. The structure and method significantly advance existing methods for reconstructive treatment for damaged peripheral nerves.